United Therapeutics (UTHR) Total Non-Current Liabilities (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Total Non-Current Liabilities data on file, last reported at $599.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 16.96% year-over-year to $599.1 million; the trailing twelve-month figure through Mar 2026 stood at $599.1 million (down 16.96% YoY), and the FY2025 full-year result was $560.6 million, down 24.05% from the prior year.
• Total Non-Current Liabilities advanced to $599.1 million in Q1 2026, from $560.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.2 billion in Q3 2023 to a low of $527.1 million in Q2 2025.
• A 5-year average of $922.7 million and a median of $1.1 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities advanced 11.49% in 2023 and plunged 43.46% in 2025, its largest moves.
• Tracing UTHR's Total Non-Current Liabilities over 5 years: stood at $1.1 billion in 2022, then fell by 3.39% to $1.1 billion in 2023, then tumbled by 33.17% to $738.1 million in 2024, then decreased by 24.05% to $560.6 million in 2025, then gained by 6.87% to $599.1 million in 2026.
• Business Quant data shows UTHR's Total Non-Current Liabilities at $599.1 million in Q1 2026, $560.6 million in Q4 2025, and $546.3 million in Q3 2025.